Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2004

01-11-2004

A phase I surrogate endpoint study of SU6668 in patients with solid tumors

Authors: Henry Q. Xiong, Roy Herbst, Silvana C. Faria, Catherine Scholz, Darren Davis, Edward F. Jackson, Timothy Madden, David McConkey, Marshall Hicks, Kenneth Hess, Chusilp (Arthur) Charnsangavej, James L. Abbruzzese

Published in: Investigational New Drugs | Issue 4/2004

Login to get access
Metadata
Title
A phase I surrogate endpoint study of SU6668 in patients with solid tumors
Authors
Henry Q. Xiong
Roy Herbst
Silvana C. Faria
Catherine Scholz
Darren Davis
Edward F. Jackson
Timothy Madden
David McConkey
Marshall Hicks
Kenneth Hess
Chusilp (Arthur) Charnsangavej
James L. Abbruzzese
Publication date
01-11-2004
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/2004
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/B:DRUG.0000036688.96453.8d

Other articles of this Issue 4/2004

Investigational New Drugs 4/2004 Go to the issue

OriginalPaper

Inhibitory effect of polypeptide from Chlamys farreri on UVA-induced apoptosis in human keratinocytes

OriginalPaper

Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: Results of a phase II study

OriginalPaper

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo

OriginalPaper

Preliminary evaluation in vitro of the inhibition of cell proliferation, cytotoxicity and induction of apoptosis by 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene

OriginalPaper

Antiproliferative effects of ZD0473 (AMD473) in combination with 5-Fluorouracil or SN38 in human colorectal cancer cell lines

OriginalPaper

Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits